Nektar Therapeutics (NKTR) Raw Materials (2010 - 2024)

Nektar Therapeutics (NKTR) posted quarterly Raw Materials of $1.7 million for Q2 2024, down 11.21% quarter-over-quarter from $1.9 million in Q1 2024.

Nektar Therapeutics (NKTR) Raw Materials (2010 - 2024) Analysis & Trends

Nektar Therapeutics' Raw Materials history runs 13 years deep, the most recent figure standing at $1.7 million for Q2 2024.

In Q2 2024, Raw Materials changed N/A year-over-year to $1.7 million; the TTM figure through Jun 2024 stood at $1.7 million (changed N/A YoY), while the FY2023 annual figure was $1.9 million, down 27.73% from the prior year.
Raw Materials for Q2 2024 stood at $1.7 million, down from $1.9 million in the prior quarter.
The five-year high for Raw Materials was $2.6 million in Q4 2022, with the low at $1.7 million in Q2 2024.
The 3-year median for Raw Materials is $1.9 million (2023), against an average of $2.0 million.
Peak annual rise in Raw Materials reached 27.73% in 2023, while the deepest fall reached 27.73% in 2023.
Nektar Therapeutics' Raw Materials stood at $2.6 million in 2022, then decreased by 27.73% to $1.9 million in 2023, then declined by 7.63% to $1.7 million in 2024.
Business Quant data shows NKTR's Raw Materials at $1.7 million in Q2 2024, $1.9 million in Q1 2024, and $1.9 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Nektar Therapeutics	1.49 Bn	919.46 Mn	3.16 Mn

Download Data